

# Health in Asia Australian Showcase

## 호주의 혁신적인 헬스 바이오텍 창업기업을 소개합니다

주한호주무역투자대표부는 한국시장으로의 확장을 희망하는 6 개의 혁신적인 호주 헬스 바이오텍 창업기업을 소개합니다. 이번 쇼케이스는 webex를 통해 시드니, 멜버른 및 퀸즐랜드로 라이브 스트리밍하여 6 개의 호주 헬스 바이오텍 창업기업이 여러분들께 피칭하는 형식으로 진행됩니다.

[참가 등록 링크](#)

### PROSPECTION

PROSPECTION

Healthcare data analytics | Series B

Founded in Sydney, Australia 2012 we are a healthcare data analytics company that aims to improve health outcomes through informed decision making. Using real world data insights to understand treatment practice, healthcare utilisation and where treatment journey can be improved. We are seeking to expand into Korea, Taiwan and China.

**Value proposition:** We work with pharmaceutical companies and researchers by integrating ourselves into our clients' business to better understand and address their challenges. Integrating multiple data sets, we use AI, technology platforms and expertise to inform better decisions. Our team offers broad experience across engineering, data science, medical and commercial industry.

[LinkedIn](#) | [Website](#)

### ResApp Health

ResApp

Digital respiratory diagnosis | Publicly listed

ResApp Health develops digital diagnostics on the basis of cough and snore sounds that can be run on a smartphone. ResApp Health has CE marked tests for asthma, COPD, pneumonia, croup, bronchiolitis and sleep apnoea.

**Value proposition:** ResAppDx aids clinicians in the diagnosis of respiratory diseases during a telehealth consult when a stethoscope or chest x-ray are unavailable or may be unnecessary. A ResAppDx test may reduce the likelihood that the patient will be referred for a further in-person consult, saving travel time and costs.

[LinkedIn](#) | [Website](#)

### genomiQa

genomiQa

Whole-genome diagnostics | Seed

genomiQa is bringing our founder's world-leading whole-genome analysis techniques to market to benefit patients. We are bringing whole-genome diagnostics to patients with cancer and rare diseases. We are helping pharma develop next-gen biomarkers to make clinical development faster and facilitate truly precise new medicines. genomiQa is a spin-out from QIMR Berghofer in Australia and seeks funding to partner to bring our diagnostics to markets in Asia.

**Value proposition:** As a Diagnostic, whole-genome avoids the diagnostic blindspots of current genomics. We see all genomic features relevant to a patient's illness. As a tool for creating biomarkers, the whole-genome allows for true discoveries, not relying on an existing hypothesis. Better biomarkers are the basis for making precision medicine more precise.

[LinkedIn](#) | [Website](#)



# Health in Asia Australian Showcase



## Minomic

Prostate cancer diagnosis | Proof of concept

Minomic is a cancer-focused diagnostics company that is commercializing a next-generation test in prostate cancer. The technology works through the implementation of a liquid biopsy, involving a blood test that can not only identify prostate cancer but also differentiate aggressive from non-aggressive tumours. The blood test, MiCheck®, utilises standardized methods to detect biomarkers present in the patient's blood and combines this with clinical factors in a proprietary algorithm that yields a "risk of aggressive prostate cancer" score. Minomic is also developing additional pipeline products in other solid tumours. e.g. pancreas.

**Value proposition:** Prostate cancer is the most common cancer in men. The current standard of care is a PSA test however 60% of men with elevated PSA levels do not have prostate cancer but still receive biopsies that are costly, traumatic and potentially infectious. MiCheck® addresses the unmet need for a test with high specificity and sufficient sensitivity to detect aggressive cancer.

[LinkedIn](#) | [Website](#)



## TALi Digital

DTx(Attention deficits) | pre Series A

TALi Digital is a Australian developer of evidence- based digital therapeutics for cognitive function. The company's vision is to be one of the global leaders in continuing to develop scalable digital therapeutic technologies to address debilitating congenital and acquired cognitive impairments, starting with conditions symptomatic of early childhood attention deficits.

**Value proposition:** TALi's first suite digital gamified solutions are clinically validated to assess and improve cognitive performance associated with attention deficits during early childhood, a critical age of development and peak neuroplasticity.

TALi's technology fulfils a need for scalable solutions to provide targeted treatment and early intervention for long-term benefits.

[LinkedIn](#) | [Website](#)



## evrima

Online clinical trial recruitment | Seed

Evrima is an online platform for clinical trial recruitment. It helps patients to search for clinical trials and connect with the providers for recruitment. Evrima's vision is to change the game in clinical research to increase access, awareness and participation. They are striving to make a global impact on clinical trial timelines and enable the industry to advance medical research swiftly so people get access to the therapies they need.

**Value proposition:** Evrima focuses on the end-to-end process of recruitment, pre-screening a referral to Sites across the full spectrum of trials and brings trials to GPs and other clinicians outside of the tertiary setting. Thereby unlocking access to a large population and increasing research as a care option in standard practice.

[LinkedIn](#) | [Website](#)

